XML 27 R13.htm IDEA: XBRL DOCUMENT v3.25.2
Note 3 - Revenue
12 Months Ended
Jun. 30, 2025
Notes to Financial Statements  
Revenue from Contract with Customer [Text Block]

Note 3 - Revenue

 

The Company disaggregates its net revenue from continuing operations by product portfolio, which for the years ended  June 30, 2025, and 2024, includes the ADHD Portfolio, comprised primarily of Adzenys and Cotempla; and the Pediatric Portfolio, comprised primarily of Karbinal, Poly-Vi-Flor and Tri-Vi-Flor. The Company’s disaggregation of revenue is consistent with its operating segment.

 

Net Revenue by Product Portfolio

 

Net revenue disaggregated by product portfolios for the years ended June 30, 2025, and 2024, were as follows:

 

  

Year Ended

 
  

June 30,

 
  

2025

  

2024

 
  

(in thousands)

 

ADHD Portfolio

 $57,576  $57,784 

Pediatric Portfolio

  8,769   7,280 

Other

  37   119 

Total net revenue

 $66,382  $65,183 

 

Other includes net revenue from various discontinued or deprioritized products. The Consumer Health business was divested in the first quarter of fiscal 2025 and is reported within discontinued operations (see Note 20 - Discontinued Operations).

 

Net Revenue by Geographic Location

 

The Company’s net revenue is predominately within the United States, with insignificant international sales.